Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: antide and hormone levels

Author： Huirne Judith A.F.   van Loenen Andre C.D.   Schats Roel   McDonnell Joseph   Hompes Peter G.A.   Schoemaker Joop   Homburg Roy   Lambalk Cornelis B.  

Publisher： Oxford University Press

ISSN： 1460-2350

Source： Human Reproduction, Vol.19, Iss.10, 2004-10, pp. : 2206-2215

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy

By Huirne Judith A.F.   van Loenen Andre C.D.   Schats Roel   McDonnell Joseph   Hompes Peter G.A.   Schoemaker Joop   Homburg Roy   Lambalk Cornelis B.  

Human Reproduction, Vol. 20, Iss. 2, 2005-02 ,pp. : 359-367

Oxford University Press

Access to resources Recommend Favorite

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®).

By ganirelix dose-finding study group The  

Human Reproduction, Vol. 13, Iss. 11, 1998-11 ,pp. : 3023-3031

Oxford University Press

Access to resources Recommend Favorite

Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone ((GnRH)) agonist and GnRH antagonist during cancer treatment in young females

By Potolog-Nahari Claris   Fishman Ami   Cohen Ilan  

Gynecological Endocrinology, Vol. 23, Iss. 5, 2007-11 ,pp. : 290-294

Informa Healthcare

Access to resources Recommend Favorite

Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol

By Orvieto Raoul   Volodarsky Michael   Hod Eduard   Homburg Roy   Rabinson Jacob   Zohav Efraim   Anteby Eyal   Meltcer Simion  

Gynecological Endocrinology, Vol. 23, Iss. 8, 2007-08 ,pp. : 494-496

Informa Healthcare

Access to resources Recommend Favorite

Timing of human chorionic gonadotropin (hCG) hormone administration in IVF/ICSI protocols using GnRH agonist or antagonists: a systematic review and meta-analysis

By Chen Ying   Zhang Yi   Hu Min   Liu Xiru   Qi Hongbo  

Gynecological Endocrinology, Vol. 30, Iss. 6, 2014-06 ,pp. : 431-437

Informa Healthcare

Access to resources Recommend Favorite